Chimeric Peptide Ganglioside Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective solutions for interacting with cell surface gangliosides to treat neurodegenerative disorders, infectious diseases, and cancers, as existing peptides fail to specifically target these sites with high affinity and specificity.
Innovation Solution
A chimeric peptide with a specific amino acid sequence, such as EGVLYVGHHT, is developed, which incorporates histidine residues to bind gangliosides like GM1 and GM3, offering enhanced affinity and specificity, and is modified for proteolytic resistance, allowing it to interact exclusively with gangliosides while ignoring neutral glycolipids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing peptides are used to target gangliosides, then they can potentially interact with cell surface glycolipids, but they fail to achieve high affinity and specificity for gangliosides like GM1 and GM3
Solution Approach 1:
The patent combines the glycolipid-binding domain from α-synuclein (residues 34-45) with the ganglioside-specific motif from Aβ (residues 5-16) to create a chimeric peptide. This merging of functional domains from two different proteins enables the chimeric peptide to achieve both high affinity and specificity for gangliosides GM1 and GM3, resolving the contradiction between binding reliability and binding quantity.
Solution Approach 2:
The chimeric peptide functions as a composite molecular structure integrating sequences from two different parental proteins. This composite design allows the peptide to inherit and combine the advantageous binding properties of both parent sequences, achieving enhanced ganglioside recognition that neither parent peptide could achieve alone.
2Ease of operation
If the peptide is designed to be short (12-20 amino acids) for ease of administration, then it can cross the blood-brain barrier more effectively, but it may be more susceptible to proteolysis
Solution Approach 1:
The patent applies chemical modifications to the chimeric peptide to alter its physical and chemical parameters, specifically introducing proteolytic resistance while maintaining its short length. These modifications enable the peptide to withstand enzymatic degradation in the bloodstream and brain, resolving the contradiction between ease of operation (BBB penetration) and compositional stability (proteolytic resistance).
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric peptide effectively prevents or treats conditions involving gangliosides by binding to GM1 and GM3, reducing neurotoxicity and inhibiting amyloid pore formation, and demonstrates potential in treating neurodegenerative disorders, infectious diseases, and cancers by crossing the blood-brain barrier and interacting with gangliosides with high specificity.
Implementation Method 1
both Aβ and α-synuclein display a common, structurally-related glycolipid-binding domain
Implementation Method 2
The high affinity of Aβ for ganglioside GM1 is determined by the presence of a pair of histidine residues (His-13 and His-14)
Implementation Method 3
Kinetics of transendothelial passage of the chimeric peptide α-syn34-45/HH through a monolayer of pure bEnd-3 cells
Implementation Method 4
Effect α-syn34-45/HH or α-syn34-45 on amyloid pore formation
Data Source
Figure 1A
Figure 1B~1C
Figure 2A~2D
AI summary
The invention relates to a chimeric peptide displaying the ganglioside-binding properties of both α-synuclein and β-amyloid peptide. Such peptide is useful in preventing or treating any condition which involves gangliosides as cell surface receptor sites, including neurodegenerative disorders, infectious diseases, or tumors.